Giao dịch Takeda Pharmaceutical Company Limited - 4502 CFD

Điều kiện giao dịch

• Loại: CFD
• Chênh lệch: 10.5
• Điều chỉnh phí tài trợ qua đêm cho vị thế mua: -0.01305%
• Điều chỉnh phí tài trợ qua đêm cho vị thế bán: -0.00917%
• Thời gian điều chỉnh phí tài trợ qua đêm: 21:00 (UTC)
• Tiền tệ: JPY
• Số lượng giao dịch tối thiểu: 1
• Biên lợi nhuận: 5.00%
• Sàn giao dịch chứng khoán: Japan
• Phí hoa hồng giao dịch: 0%
• Bảo đảm dừng phí bảo hiểm: 1%

Số liệu thống kê chính

• Trước đó Đóng: 5110.38
• Mở: 4948.84
• Thay đổi 1 năm: 14.61%
• Phạm vi trong ngày: 4859.13 - 4948.84

Giao dịch Takeda Pharmaceutical Company Limited - 4502 CFD

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a corporate strategic research alliance with Egle Therapeutics SAS to uncover novel tumor-specific regulatory t-cell targets and develop unique anti-suppressor-based immunotherapies; a strategic partnership with Neurocrine Biosciences, Inc. to develop and commercialize therapies for psychiatric disorders; and Carmine Therapeutics to discover, develop, and commercialize transformative non-viral gene therapies for two rare diseases. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.